why choose us

First received: April 10, 2023

Clinical Trial: Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

Study Status: Completed

Recruit Status: RECRUITING

Condition: Leukemia, Acute

Study Type: INTERVENTIONAL


Official Title: Phase 1a/1b Study of Itacitinib (INCB039110) for Cytokine Release Syndrome Prevention and Minimization of Immunosuppression Following Nonmyeloablative Related Partially HLA-mismatched Peripheral

Brief Summary: This research is being done to learn whether drug called itacitinib, which is a novel inflammation- and immune-lowering drug (immunosuppressant), can be given before and after non-myeloablative peripheral blood stem cell transplantation (PBSCT; also known as a 'mini' transplant) to help prevent certain complications such as cytokine release syndrome (CRS) for patients with blood cancers, using peripheral blood from a relative.The investigators will also examine if by using itacitinib the investigators…

Read more